Anthem Biosciences (ANTHEM) Q1 FY27 Profit Falls Less Than Revenue as Margins Defend
A sharp drop in quarterly revenue was cushioned by resilient profitability, as management blames timing shifts and points to a strong order book for recovery.
Anthem Biosciences saw Q1 FY27 revenue fall 22.6% year-on-year to ₹418 crore, but net profit declined a narrower 11.7% to ₹120 crore. The company maintained strong margins, attributing the top-line weakness to customer delivery schedules.
For a contract research and manufacturing firm, the rhythm of customer shipments dictates the quarterly scorecard. Anthem Biosciences’ first quarter of FY27 saw that rhythm pause, as key deliveries shifted into later periods, leaving revenue significantly lower but profitability surprisingly intact.
Consolidated revenue fell 22.6% from a year ago to ₹418.2 crore, and dropped 31.5% from the prior quarter. Net profit declined 11.7% year-on-year to ₹119.9 crore. The divergence tells the story: the net profit margin expanded by 360 basis points to 28.7%, as cost discipline softened the blow of lower sales.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Period | Jun 2026 | Mar 2026 | Jun 2025 |
| Revenue (₹ Cr) | 418.22YoY -23% | 610.94 | 540.21 |
| Profit (₹ Cr) | 119.94YoY -12% | 189.76 | 135.79 |
| Net Profit Margin (%) | 28.7YoY +14% | 31.1 | 25.1 |
Why the Top Line Stumbled
Management, in calls covered by Investing.com and Multibagg.ai, was clear: this was a timing issue, not a demand problem. Deliveries for several key CRDMO (Contract Research, Development, and Manufacturing) projects were deferred by clients into the second half of the fiscal year. This segment, which contributes over 80% of revenue, saw sales drop 24.7% year-on-year to ₹341 crore, according to ScanX.trade.
The smaller Specialty Ingredients business also faced headwinds from raw material supply chain turbulence. The result was a quarter where overall capacity utilization dipped, with Unit 2 running at about 50%, as noted in a SOIC Substack analysis.
How Margins Held Their Ground
Even as revenue fell, Anthem’s profitability metrics showed resilience. EBITDA margin expanded 153 basis points year-on-year to 39.6%, as reported by Businessworld. Management credited a “disciplined focus on cost efficiencies, yield optimisation, and employee productivity.”
The reported profit decline was also cushioned by a one-off item. A deferred-tax credit of about ₹10.1 crore pulled the effective tax rate down to 17%, according to Stockwatch.live. Excluding this, the underlying profit fall would have been closer to 19% year-on-year.
The Visibility for a Comeback
The central pillar of management’s confidence is a strong order book. The company told analysts it has visibility into about 60% of its full-year FY27 revenue needs, a figure that was replenished even after the soft Q1. This, coupled with the expectation that deferred shipments will land in Q2 through Q4, frames Q1 as the anticipated trough.
The long-term growth engine remains a massive capacity expansion. The company is investing ₹1,200 crore in Unit 4, with ₹700 crore earmarked for FY27, aiming to double custom synthesis capacity by the end of FY28.
Key Points
- Revenue declined sharply due to timing shifts in customer deliveries, particularly in the core CRDMO segment, but underlying demand is stated to be intact.
- Profitability was defended through cost controls, with the net profit margin improving to 28.7% despite the revenue drop, though aided by a lower tax rate.
- Management maintains full-year confidence, backed by a 60% order book visibility and the expectation that postponed shipments will materialize in the coming quarters.
- A major ₹1,200 crore capacity expansion (Unit 4) is underway, with significant capex planned for FY27 to support future growth.
Hexa Perspective
The quarter presents a clear tension between a weak headline and a resilient underlying model. The steep revenue drop validates the inherent lumpiness of the CRDMO business, a risk investors must price in. Yet, the defense of industry-leading margins and the solid order book suggest the operational framework is sound.
The coming quarters will test management's timing narrative. Success hinges on converting that 60% order book and ramping up utilization in existing units. With a premium valuation of 62 times earnings, the stock has little room for error if the promised H2 recovery falters.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.